Prenetics Global Limited Logo

Prenetics Global Limited

PRE

(0.5)
Stock Price

4,36 USD

-19.54% ROA

-19.78% ROE

-1.13x PER

Market Cap.

51.677.826,00 USD

2.34% DER

0% Yield

-55.53% NPM

Prenetics Global Limited Stock Analysis

Prenetics Global Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Prenetics Global Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (3%), which means it has a small amount of debt compared to the ownership it holds

2 ROE

The stock's ROE indicates a negative return (-20.75%) on shareholders' equity, suggesting poor financial performance.

3 ROA

The stock's ROA (-19.78%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

4 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.42x) suggests it's overvalued, potentially making it an expensive investment.

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-352) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Prenetics Global Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Prenetics Global Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Prenetics Global Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Prenetics Global Limited Revenue
Year Revenue Growth
2019 9.233.089
2020 65.179.515 85.83%
2021 275.852.753 76.37%
2022 275.761.298 -0.03%
2023 19.462.088 -1316.92%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Prenetics Global Limited Research and Development Expenses
Year Research and Development Expenses Growth
2019 2.989.758
2020 2.782.123 -7.46%
2021 10.563.952 73.66%
2022 15.519.228 31.93%
2023 15.922.480 2.53%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Prenetics Global Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 13.185.125
2020 16.616.462 20.65%
2021 83.991.413 80.22%
2022 96.063.312 12.57%
2023 43.009.528 -123.35%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Prenetics Global Limited EBITDA
Year EBITDA Growth
2019 -18.516.163
2020 -564.776 -3178.5%
2021 -162.442.998 99.65%
2022 43.216.608 475.88%
2023 -54.482.884 179.32%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Prenetics Global Limited Gross Profit
Year Gross Profit Growth
2019 2.715.294
2020 26.344.819 89.69%
2021 106.131.211 75.18%
2022 131.554.886 19.33%
2023 6.494.104 -1925.76%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Prenetics Global Limited Net Profit
Year Net Profit Growth
2019 -20.195.201
2020 -1.963.885 -928.33%
2021 -174.016.842 98.87%
2022 -190.453.387 8.63%
2023 -54.281.820 -250.86%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Prenetics Global Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 -3
2020 0 0%
2021 -24 100%
2022 -38 37.84%
2023 -5 -825%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Prenetics Global Limited Free Cashflow
Year Free Cashflow Growth
2019 -2.256.968
2020 -5.939.772 62%
2021 2.004.237 396.36%
2022 8.171.892 75.47%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Prenetics Global Limited Operating Cashflow
Year Operating Cashflow Growth
2019 -1.883.110
2020 -2.879.711 34.61%
2021 13.416.497 121.46%
2022 14.514.596 7.57%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Prenetics Global Limited Capital Expenditure
Year Capital Expenditure Growth
2019 373.858
2020 3.060.061 87.78%
2021 11.412.260 73.19%
2022 6.342.704 -79.93%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Prenetics Global Limited Equity
Year Equity Growth
2020 31.007.007
2021 -400.894.913 107.73%
2022 240.038.123 267.01%
2023 228.784.204 -4.92%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Prenetics Global Limited Assets
Year Assets Growth
2020 78.883.311
2021 148.507.321 46.88%
2022 307.976.609 51.78%
2023 276.414.567 -11.42%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Prenetics Global Limited Liabilities
Year Liabilities Growth
2020 47.876.304
2021 549.402.234 91.29%
2022 67.938.486 -708.68%
2023 47.630.363 -42.64%

Prenetics Global Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
6.86
Net Income per Share
-3.81
Price to Earning Ratio
-1.13x
Price To Sales Ratio
0.64x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
0.22
EV to Sales
0.02
EV Over EBITDA
-0.07
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
-0.89
FreeCashFlow Yield
0
Market Cap
0,05 Bil.
Enterprise Value
0,00 Bil.
Graham Number
40.48
Graham NetNet
2.51

Income Statement Metrics

Net Income per Share
-3.81
Income Quality
0
ROE
-0.2
Return On Assets
-0.16
Return On Capital Employed
-0.11
Net Income per EBT
1.24
EBT Per Ebit
1.43
Ebit per Revenue
-0.31
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
0.64
Research & Developement to Revenue
0.17
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.48
Operating Profit Margin
-0.31
Pretax Profit Margin
-0.45
Net Profit Margin
-0.56

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.11
Return on Tangible Assets
-0.2
Days Sales Outstanding
39.71
Days Payables Outstanding
30.58
Days of Inventory on Hand
28.64
Receivables Turnover
9.19
Payables Turnover
11.94
Inventory Turnover
12.75
Capex per Share
0

Balance Sheet

Cash per Share
5,86
Book Value per Share
19,11
Tangible Book Value per Share
15.44
Shareholders Equity per Share
19.11
Interest Debt per Share
0.45
Debt to Equity
0.02
Debt to Assets
0.02
Net Debt to EBITDA
2.03
Current Ratio
2.61
Tangible Asset Value
0,18 Bil.
Net Current Asset Value
0,06 Bil.
Invested Capital
0.02
Working Capital
0,06 Bil.
Intangibles to Total Assets
0.17
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
3529532
Debt to Market Cap
0.1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Prenetics Global Limited Dividends
Year Dividends Growth

Prenetics Global Limited Profile

About Prenetics Global Limited

Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

CEO
Mr. Sheng Wu Yeung
Employee
400
Address
Unit 701-706, K11 Atelier King’s Road
Quarry Bay,

Prenetics Global Limited Executives & BODs

Prenetics Global Limited Executives & BODs
# Name Age
1 Ms. Yvonne L. Wong
Chief Corporate Development Officer
70
2 Mr. Sheng Wu Yeung
Co-Founder & Chief Executive Officer
70
3 Mr. Hoi Chun Lo
Chief Financial Officer
70
4 Dr. Chi Hung Tzang Ph.D.
Co-Founder, Chief Scientific Officer & Member of Scientific Advisory Board
70
5 Dr. Shih-Chang Ong M.D.
Chief Medical Officer & Member of Scientific Advisory Board
70
6 Mr. Joel Neoh
Chief Consumer Officer & MD for CircleDNA
70
7 Dr. Yung Ho Wong DPHIL
Chief Technology Officer
70
8 Ms. Samantha Kwok
Vice President People & Culture
70
9 Dr. Senthil Sundaram M.D.
Chief Clinical Officer
70
10 Mr. Avrom Boris Lasarow
Chief Executive Officer of EMEA
70

Prenetics Global Limited Competitors